Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Westlake Village BioPartners does not develop drugs themselves but invests in and incubates early-stage life science companies developing transformative medicines. Their portfolio includes companies at all stages from preclinical through IPO or acquisition. Recent notable exits include IPOs and acquisitions such as Acelyrin’s IPO and Kate Therapeutics’ acquisition. The firm has raised over $1.3 billion since its founding in 2018 across three funds. They are recognized for catalyzing the Los Angeles biotech ecosystem by supporting entrepreneurs from ideation through clinical development to commercialization.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Westlake Village BioPartners.